Clinical

Dataset Information

0

A Randomized Trial of Adjuvant Chemotherapy with UFT / LV versus PSK / UFT / LV following curative resection for Stage II / III Colorectal Cancer


ABSTRACT: Interventions: Group A (standard therapy group:UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group: PSK/UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 6 months. Group C (trial therapy group: PSK/UFT/LV 12M): Administration of 10 courses (12 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 12 months. Primary outcome(s): 3 year desease free survival rate Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2620921 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2609649 | ecrin-mdr-crc
| 2621031 | ecrin-mdr-crc
| 2610281 | ecrin-mdr-crc
| 97801 | ecrin-mdr-crc
| 2614159 | ecrin-mdr-crc
| 2615636 | ecrin-mdr-crc
| 2723206 | ecrin-mdr-crc
| 2616118 | ecrin-mdr-crc
| 2723211 | ecrin-mdr-crc
| 2020230 | ecrin-mdr-crc